Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Japan
Clinical trial register · Japan

Clinical Trials in Japan

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2517 matching records held by the registry are in this view. Synced 15 Nov 2026, 03:19 UTC
2517
Studies in scope
all four open statuses
1288
Recruiting now
open to new participants
355
Lead sponsors
across recruiting studies
Top sites
Fukuoka 7 Kobe 5 Hidaka-shi 4 Tokyo 4 Kagoshima 4

Trials in this register

19 of 2517 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
Incyte Corporation
Phase 3
426
Bunkyō City, Chūō, Fukuoka, Fukushima, Hirakata, Kagoshima, Kashiwa-shi, Kobe
2026-09-08
Recruiting
Incyte Corporation
Phase 1
218
Kashiwa Chiba, Toon, Ehime
2026-05-11
Recruiting
Incyte Corporation
Phase 3
588
Akashi, HYGO, Fukuoka Fukuoka, Kahoku-gun, Kitaadachi-gun, Kōtoku, Mitaka-shi, Osaka, Sapporo Hokkaido
2026-04-09
Recruiting
Incyte Corporation
Phase 3
700
Akashi-shi, Chiba, Chūōku, Fukuoka, Hidaka-shi, Kashiwa-shi, Kawasaki-shi, Kita-gun
2026-03-05
Recruiting
Incyte Corporation
Phase 3
466
Akashi-shi, Hidaka-shi, Kōtoku, Kurume, Matsuyama, Minatoku, Nagoya, Okayama
2025-12-09
Recruiting
Incyte Corporation
Phase 2
160
Akashi-shi, Hidaka-shi, Kōtoku, Kurume, Matsuyama, Sapporo, Sunto-gun
2025-11-12
Recruiting
Incyte Corporation
Phase 3
240
Aichi, Aichi-ken, Fukuoka, Hiroshima, Hyōgo, Isehara Kanagawa, Kumamoto Kumamoto, Maebashi
2025-01-21
Active, closed
Incyte Corporation
Phase 3
346
Bunkyō City, Inashiki-gun, Kamimashiki-gun, Kawasaki-shi, Kitakyushu, Kobe, Kumamoto, Minamikoshigaya
2024-10-10
Active, closed
Incyte Corporation
Phase 3
617
Ginowan-shi, Kurume-shi, Kyoto, Niigata, Sapporo, Sendai, Shinjuku-ku, tabashi City
2024-01-30
Recruiting
Incyte Corporation
Phase 1
710
Chiba, Tokyo
2024-01-04
Active, closed
Incyte Corporation
Phase 3
467
Hamamatsu, Kawasaki, Kobe, Kyoto, Minamikoshigaya, Nagasaki, Nagoya, Nankoku
2023-11-29
Active, closed
Incyte Corporation
Phase 1
160
Chiba-ken, Kagoshima, Osaka, Tokyo, Tsu
2023-09-25
Recruiting
Incyte Corporation
Phase 1
570
Hirakata, Tokyo
2023-07-24
Active, closed
Incyte Corporation
Phase 2
247
Chūōku, Fukuoka, Kishiwada, Kitakyushu-shi, Mizunami-shi, Osaka, Sakaide-shi, Sapporo
2023-07-11
Active, closed
Incyte Corporation
Phase 1
291
Aichi, Chiba-ken, Hidaka-shi, Tokyo
2022-07-05
Active, closed
Incyte Corporation
Phase 3
899
Fukuoka, Gifu, Ibaraki, Isehara, Kagoshima, Nagoya, Narita-shi, Okayama
2021-05-11
Active, closed
Incyte Corporation
Phase 3
654
Fukuoka, Fukuyama-shi, Gifu, Kagoshima, Kashiwa-shi, Kitakyushu-shi, Kobe, Nagoya
2021-04-15
Active, closed
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
NCT04279847Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm
Incyte Corporation
Phase 1
140
Aichi, Chiba, Chūō, Fukuoka, Kumamoto
2021-02-23
Active, closed
Incyte Corporation
Phase 2
112
Bunkyō City, Chūō, Hirakata, Isehara, Kobe, Kyoto, Matsumoto-shi, Miyagi
2020-08-03
Rows per page Showing 1–19 of 19
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 17 November 2026. https://priyalifescience.com/clinical-trials-japan

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,517 studies in total at the last sync on 15 Nov 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 19 of those studies that match the filters currently applied.

How many clinical trials are recruiting in Japan?

9 of the 19 studies on this page are recruiting new participants as of the 15 Nov 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 10 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase, 19 studies
PhaseStudiesRecruitingShare
Phase 310552.6%
Phase 16331.6%
Phase 23115.8%

Most active sponsors

Lead sponsors with the most studies
Lead sponsorStudiesRecruiting
Incyte Corporation199

This register, in your inbox every Friday

One email a week with how many trials are recruiting in Ireland, new EMA and FDA approvals and medicine shortages, built from the same public registers as this page.

Free. Unsubscribe from any email with one click. See our privacy policy.

→

Browse trials by condition

Solid Tumors (4) Myeloproliferative Neoplasms (2) Ovarian Cancer (2) Advanced Solid Tumors (1) Metastatic Solid Tumors (1) Moderate to Severe Asthma (1) Diffuse Large B-cell Lymphoma (1) Follicular Lymphoma (1) Marginal Zone Lymphoma (1) Prurigo Nodularis (1) B-Cell Malignancies (1) Essential Thrombocythemia (1) Hidradenitis Suppurativa (HS) (1) NonSegmental Vitiligo (1) CRC (Colorectal Cancer) (1)
→

Browse trials by site location

Fukuoka (7) Kobe (5) Hidaka-shi (4) Tokyo (4) Kagoshima (4) Nagoya (4) Aichi (3) Hirakata (3) Osaka (3) Sapporo (3) Kōtoku (3) Kashiwa-shi (3) Bunkyō City (3) Chūō (3) Kyoto (3)
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.